Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPersimmon Regulatory News (PSN)

Share Price Information for Persimmon (PSN)

Share Price is delayed by 15 minutes
Get Live Data
1,078.50    26.00 (2.47%)
Bid:
1,071.00
Ask:
1,072.00
Spread: 1.00 (0.093%)
Market Cap: £3.46b
PSN Live PriceLast checked at - London Stock Exchange

Intraday Persimmon Share Chart

Interim Management Statement

23 Apr 2009 07:00

RNS Number : 0200R
Persimmon PLC
23 April 2009
 



Thursday 23 April 2009

Persimmon plc

INTERIM MANAGEMENT STATEMENT

Persimmon plc is holding its Annual General Meeting at 12 noon today at York Racecourse where the following comments will be made regarding current trading, financial performance and the outlook for the financial year. This statement covers the period from 1 January 2009 to the date of this announcement and constitutes Persimmon plc’s first quarter Interim Management Statement as required by the UK Listing Authority’s Disclosure and Transparency Rules.

 

Sales volumes for the first sixteen weeks of the year have continued to be ahead of our expectations. Pricing and margins however have remained under pressure. We currently have c. 6,500 homes reserved, contracted or legally completed with total sales revenue of c. £960 million

In line with our current trading review provided at the time of our preliminary announcement on 3 March 2009, visitor levels to our sites for the year to date remain resilient despite being c. 15% down on the level for the same period last year. In addition, cancellation rates over the same period have averaged c. 16% representing an improvement over c. 35% cancellation rate for the last quarter of 2008.

We are currently operating from c. 16% fewer active sites than at the same point last year. Despite this, sales volumes over recent weeks have been ahead of those achieved in the comparative weeks of April last year when we experienced a significant deterioration in market conditions.

We continue to focus on rigorous control over working capital which is reflected in the reduction in our active sites and in our holdings of part-exchange property which is currently at a level of c. £30 million (31 December 2008: £55 million).

On 13 March 2009 we announced the finalisation of documentation in respect of the refinancing of our business through to 31 March 2012. At the end of March, which is approaching our traditional seasonal working capital peak in April, our borrowings were c. £680 million (March 2008: £1,030 million). Our debt levels are expected to reduce further this year and we continue to monitor the land market as previously outlined.

Whilst the recent improvement in market conditions is encouraging, we will remain cautious about the outlook until mortgage availability improves further and employment prospects become less uncertain.

We are, however, confident that our position in the market will provide a strong platform for growth when the market improves.

For further information, please contact:

Persimmon plc +44 (0) 1904 642 199

Mike Farley, Group Chief Executive

Mike Killoran, Group Finance Director

M: Communications

Edward Orlebar +44 (0) 207 153 1523 / +44 (0) 7738 724 630

Charlotte McMullen +44 (0) 207 153 1549 / +44 (0) 7921 881 800

Marylene Guernier +44 (0) 207 153 1269 / +44 (0) 7776 303 788

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSUUVBRKURSUAR
Date   Source Headline
1st May 20257:00 amRNSAGM Trading Statement
25th Apr 202510:54 amRNSHolding(s) in Company
25th Apr 20259:24 amRNSHolding(s) in Company
11th Apr 20254:22 pmRNSHolding(s) in Company
3rd Apr 202510:15 amRNSHolding(s) in Company
2nd Apr 202512:22 pmRNSHolding(s) in Company
1st Apr 202512:03 pmRNSTotal Voting Rights
31st Mar 20253:14 pmRNSDirector/PDMR Shareholding
27th Mar 202510:08 amRNSHolding(s) in Company
25th Mar 20253:14 pmRNSDirector/PDMR Shareholding
24th Mar 20253:35 pmRNSAnnual Report 2024 and Notice of AGM 2025
24th Mar 20252:24 pmRNSHolding(s) in Company
11th Mar 20257:00 amRNSFull Year Results
6th Mar 20252:06 pmRNSHolding(s) in Company
3rd Mar 20253:35 pmRNSHolding(s) in Company
3rd Feb 202512:26 pmRNSTotal Voting Rights
14th Jan 20257:00 amRNS2024 Trading Statement
2nd Jan 20251:00 pmRNSTotal Voting Rights
10th Dec 20243:47 pmRNSDirectorate Change
2nd Dec 20242:11 pmRNSBlock listing Interim Review
2nd Dec 202412:00 pmRNSTotal Voting Rights
6th Nov 20247:00 amRNSQ3 Trading Statement
5th Nov 20241:31 pmRNSHolding(s) in Company
1st Nov 20243:59 pmRNSTotal Voting Rights
1st Oct 20241:19 pmRNSTotal Voting Rights
24th Sep 202412:25 pmRNSDirector/PDMR Shareholding
2nd Sep 20241:44 pmRNSTotal Voting Rights
8th Aug 20247:00 amRNSHalf Year Results
1st Aug 20242:32 pmRNSTotal Voting Rights
23rd Jul 202410:28 amRNSDirectorate Change
1st Jul 20241:10 pmRNSTotal Voting Rights
19th Jun 20242:48 pmRNSDirector/PDMR Shareholding
3rd Jun 202412:33 pmRNSBlock listing Interim Review
3rd Jun 202411:08 amRNSTotal Voting Rights
23rd May 20247:00 amRNSConfirmation of CFO start date
1st May 20241:11 pmRNSTotal Voting Rights
30th Apr 20242:03 pmRNSDirectorate Change
25th Apr 20242:09 pmRNSResult of AGM
25th Apr 20247:00 amRNSQ1 Trading Statement
2nd Apr 20241:49 pmRNSTotal Voting Rights
28th Mar 202412:53 pmRNSDirector/PDMR Shareholding
25th Mar 20244:47 pmRNSDirector/PDMR Shareholding
25th Mar 20242:07 pmRNSAnnual Report 2023 and Notice of AGM 2024
12th Mar 20241:38 pmRNSDirector/PDMR Shareholding
12th Mar 20247:00 amRNSFull Year Results
11th Jan 20246:00 pmRNSDechra Pharmaceuticals
10th Jan 20247:00 amRNSTrading Statement
1st Dec 20234:48 pmRNSBlock listing Interim Review
1st Dec 20234:45 pmRNSTotal Voting Rights
17th Nov 202310:25 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.